{"id":"https://openalex.org/W2607362117","doi":"https://doi.org/10.1080/13696998.2017.1307204","title":"Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States","display_name":"Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States","publication_year":2017,"publication_date":"2017-03-15","ids":{"openalex":"https://openalex.org/W2607362117","doi":"https://doi.org/10.1080/13696998.2017.1307204","mag":"2607362117","pmid":"https://pubmed.ncbi.nlm.nih.gov/28294645"},"language":"en","primary_location":{"id":"doi:10.1080/13696998.2017.1307204","doi":"https://doi.org/10.1080/13696998.2017.1307204","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1307204","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1307204?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1307204?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031277779","display_name":"Catherine Saint\u2010Laurent Thibault","orcid":"https://orcid.org/0000-0002-5415-1045","observed_orcids":["https://orcid.org/0000-0002-5415-1045"]},"institutions":[{"id":"https://openalex.org/I60158472","display_name":"Concordia University","ror":"https://ror.org/0420zvk78","country_code":"CA","type":"education","lineage":["https://openalex.org/I60158472"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Catherine Saint-Laurent Thibault","raw_affiliation_strings":["Evidera, Montreal, QC, Canada;"],"raw_orcid":"https://orcid.org/0000-0002-5415-1045","affiliations":[{"raw_affiliation_string":"Evidera, Montreal, QC, Canada;","institution_ids":["https://openalex.org/I60158472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026399519","display_name":"Divya Moorjaney","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Divya Moorjaney","raw_affiliation_strings":["QuickPivot, Boston, MA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"QuickPivot, Boston, MA, USA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047100651","display_name":"Michael Lee Ganz","orcid":"https://orcid.org/0000-0002-9702-2999","observed_orcids":["https://orcid.org/0000-0002-9702-2999"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael L. Ganz","raw_affiliation_strings":["Evidera, Waltham, MA, USA;"],"raw_orcid":"https://orcid.org/0000-0002-9702-2999","affiliations":[{"raw_affiliation_string":"Evidera, Waltham, MA, USA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077726343","display_name":"Bruce E. Sill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Sill","raw_affiliation_strings":["Bristol-Myers Squibb, Hartford, CT, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Hartford, CT, USA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017001582","display_name":"Shalini Hede","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shalini Hede","raw_affiliation_strings":["Bristol-Myers Squibb, Plainsboro, NJ, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Plainsboro, NJ, USA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010376603","display_name":"Yong Yuan","orcid":"https://orcid.org/0000-0001-9720-1965","observed_orcids":["https://orcid.org/0000-0001-9720-1965"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yong Yuan","raw_affiliation_strings":["Bristol-Myers Squibb, Plainsboro, NJ, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Plainsboro, NJ, USA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024291639","display_name":"Boris Gorsh","orcid":"https://orcid.org/0000-0001-6977-0220","observed_orcids":["https://orcid.org/0000-0001-6977-0220"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Boris Gorsh","raw_affiliation_strings":["GlaxoSmithKline, Upper Providence, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Upper Providence, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5031277779"],"corresponding_institution_ids":["https://openalex.org/I60158472"],"apc_list":null,"apc_paid":null,"fwci":1.0123,"has_fulltext":true,"cited_by_count":7,"citation_normalized_percentile":{"value":0.757465,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"20","issue":"7","first_page":"692","last_page":"702"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.7554000020027161,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.7554000020027161,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.24279999732971191,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daclatasvir","display_name":"daclatasvir","score":0.8629999756813049},{"id":"https://openalex.org/keywords/sofosbuvir","display_name":"sofosbuvir","score":1.0},{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.8980000019073486},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8669999837875366},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.9160000085830688},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.8209999799728394},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.906000018119812},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9129999876022339},{"id":"https://openalex.org/keywords/liver-cirrhosis","display_name":"liver cirrhosis","score":0.7409999966621399},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.8379999995231628},{"id":"https://openalex.org/keywords/payer-perspective","display_name":"payer perspective","score":0.7020000219345093}],"concepts":[{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.8878073692321777},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8720943927764893},{"id":"https://openalex.org/C2776979040","wikidata":"https://www.wikidata.org/wiki/Q5207712","display_name":"Daclatasvir","level":5,"score":0.8031622171401978},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5386362671852112},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.502591609954834},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.50213623046875},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4454708695411682},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.44020816683769226},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4354203939437866},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.4344901144504547},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.3237733840942383},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.1548917591571808},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0858752429485321},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069474","descriptor_name":"Sofosbuvir","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000069474","descriptor_name":"Sofosbuvir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002219","descriptor_name":"Carbamates","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018803","descriptor_name":"Models, Economic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1080/13696998.2017.1307204","doi":"https://doi.org/10.1080/13696998.2017.1307204","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1307204","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1307204?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:28294645","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28294645","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"},{"id":"pmid:28745536","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28745536","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/13696998.2017.1307204","doi":"https://doi.org/10.1080/13696998.2017.1307204","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2017.1307204","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1307204?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2607362117.pdf","grobid_xml":"https://content.openalex.org/works/W2607362117.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W1971610182","https://openalex.org/W1984413237","https://openalex.org/W1993189159","https://openalex.org/W2003104968","https://openalex.org/W2011437704","https://openalex.org/W2016970194","https://openalex.org/W2021704384","https://openalex.org/W2027689857","https://openalex.org/W2035804055","https://openalex.org/W2043484880","https://openalex.org/W2054882786","https://openalex.org/W2055983460","https://openalex.org/W2066074857","https://openalex.org/W2070851574","https://openalex.org/W2082508303","https://openalex.org/W2087749147","https://openalex.org/W2091436715","https://openalex.org/W2097068106","https://openalex.org/W2106378149","https://openalex.org/W2106485849","https://openalex.org/W2106791445","https://openalex.org/W2139944544","https://openalex.org/W2145134431","https://openalex.org/W2145328124","https://openalex.org/W2147658767","https://openalex.org/W2150652264","https://openalex.org/W2153507115","https://openalex.org/W2160626977","https://openalex.org/W2164439784","https://openalex.org/W2173897984","https://openalex.org/W2189030627","https://openalex.org/W2289667014","https://openalex.org/W2292517844","https://openalex.org/W2294421604","https://openalex.org/W2329262502","https://openalex.org/W2344756272","https://openalex.org/W2525430360","https://openalex.org/W2567894674"],"related_works":["https://openalex.org/W4234643552","https://openalex.org/W2292517844","https://openalex.org/W2737144189","https://openalex.org/W2399911729","https://openalex.org/W2343758234","https://openalex.org/W2563831061","https://openalex.org/W2736385608","https://openalex.org/W2179578763","https://openalex.org/W2804623264","https://openalex.org/W2344756272"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1,63],"phase":[2],"III":[3],"trial":[4],"evaluated":[5,34],"the":[6,35,54,93,102,119,166,201,213,257,260],"efficacy":[7],"and":[8,82,86,95,118,130,143,158,169,182,203],"safety":[9],"of":[10,22,37,56,77,108,111,179,215,234],"Daklinza":[11],"(daclatasvir":[12],"or":[13],"DCV)":[14],"in":[15,43,165,170,200,212,232,256],"combination":[16,44],"with":[17,45,155,239,252],"sofosbuvir":[18],"(SOF)":[19],"for":[20,218,259],"treatment":[21,74,220],"genotype":[23],"(GT)":[24],"3":[25,263],"hepatitis":[26],"C":[27],"virus":[28],"(HCV)":[29],"patients.":[30],"AIM:":[31],"This":[32],"study":[33],"cost-effectiveness":[36],"DCV":[38,150,185,222,244],"+":[39,151,163,186,198,223,241,245,254],"SOF":[40,42,152,162,187,197,224,240,246,253],"vs":[41],"ribavirin":[46],"(RBV)":[47],"over":[48],"a":[49,57,248],"20-year":[50],"time":[51,177],"horizon":[52],"from":[53,92],"perspective":[55],"United":[58],"States":[59],"(US)":[60],"payer.":[61],"METHODS:":[62],"published":[64],"Markov":[65],"model":[66],"was":[67,101,153,188],"adapted":[68],"to":[69,210],"reflect":[70],"US":[71,258],"demographic":[72],"characteristics,":[73],"patterns,":[75],"costs":[76,157,225],"drug":[78],"acquisition,":[79],"monitoring,":[80],"disease":[81],"adverse":[83],"event":[84],"management,":[85],"mortality":[87],"risks.":[88],"Clinical":[89],"inputs":[90],"came":[91],"ALLY-3":[94],"VALENCE":[96],"trials.":[97],"The":[98],"primary":[99],"outcome":[100],"incremental":[103],"cost-utility":[104],"ratio.":[105],"Life-years,":[106],"incidence":[107],"complications,":[109],"number":[110],"patients":[112],"achieving":[113,216],"sustained":[114],"virological":[115],"response":[116],"(SVR),":[117],"total":[120],"cost":[121],"per":[122,139,229],"SVR":[123,217],"were":[124,135,147,208],"secondary":[125],"outcomes.":[126],"Costs":[127],"(2014":[128],"USD)":[129],"quality-adjusted":[131],"life":[132],"years":[133],"(QALYs)":[134],"discounted":[136],"at":[137],"3%":[138],"year.":[140],"Deterministic,":[141],"probabilistic,":[142],"scenario":[144],"sensitivity":[145],"analyses":[146],"conducted.":[148],"RESULTS:":[149],"associated":[154],"lower":[156],"better":[159],"effectiveness":[160],"than":[161,196,227],"RBV":[164,199,255],"base":[167],"case":[168],"almost":[171],"all":[172,235],"scenarios":[173],"(i.e.":[174],"treatment-experienced,":[175],"non-cirrhotic,":[176],"horizons":[178],"5,":[180],"10,":[181],"80":[183],"years).":[184],"less":[189,194,226],"costly,":[190],"but":[191],"also":[192],"slightly":[193],"effective":[195],"cirrhotic":[202],"treatment-na\u00efve":[204],"population":[205],"scenarios.":[206],"Results":[207],"sensitive":[209],"variations":[211],"probability":[214],"both":[219],"arms.":[221],"$50,000":[228],"QALY":[230],"gained":[231],"79%":[233],"probabilistic":[236],"iterations":[237],"compared":[238,251],"RBV.":[242],"CONCLUSION:":[243],"is":[247],"dominant":[249],"option":[250],"overall":[261],"GT":[262],"HCV":[264],"patient":[265],"population.":[266]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-04-28T00:00:00"}